Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

Pharmaceutical Supply of Labetalol Hydrochloride Injection

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract entails the manufacture and supply of four units of Labetalol Hydrochloride Injection USP, 5 mg/mL in 40 mL vials, strictly adhering to FDA regulations, current Good Manufacturing Practices, and specialized military labeling standards. The product is identified by NSN 6505012579990 and is intended for use within the Department of Defense’s medical supply chain, ensuring compatibility with military pharmacopeial and logistical requirements. Production and delivery must meet all quality assurance benchmarks mandated for federal medical procurement, with full compliance documented to support inventory integration and battlefield readiness. Subcontracted under the NAICS code 325412 for Pharmaceutical Preparation Manufacturing, the solicitation was posted on July 20, 2026, with responses due by July 27, 2026. The place of performance is designated as Fort Stewart, Georgia, with a ZIP code of 31314-5185, indicating the primary logistics and distribution hub for the delivered product. The contracting entity is the Medical Supply Chain Pharm FSA under the Department of Defense, and the official request can be accessed via the DIBBS portal, underscoring the transaction’s direct alignment with military pharmaceutical procurement protocols.

General Info

Manufacture and supply four Labetalol Hydrochloride Injection USP vials per military specs for Fort Stewart, Georgia.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSAView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

FORT STEWART, GA, 31314-5185, US

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Manufacture and supply of 4 units of Labetalol Hydrochloride Injection USP, 5 mg/mL, 40 mL vial (NSN: 6505012579990), compliant with FDA, cGMP, and military labeling standards.

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
DIBBS
Medical Chemical Formulation and ManufacturingThe contract involves the manufacture of a modified 0.125 percent sodium hypochlorite solution, known as Dakins Solution Quarter Strength, packaged in 480 mL bottles. The scope includes full formulation development, rigorous quality control protocols, batch-by-batch testing to ensure consistency and safety, and strict compliance with medical-grade standards to meet regulatory requirements for clinical use. All production activities must adhere to guidelines ensuring sterility, stability, and purity, as the final product is intended for medical applications requiring precise chemical concentrations and contamination-free packaging. The contract is classified as a subcontract under NAICS code 325412 for pharmaceutical and medicine manufacturing, issued by the Department of Defense through the Medical Supply Chain Pharm FSA. It was posted on July 20, 2026, with a response deadline of July 27, 2026, and the performance location is not specified, implying flexibility in manufacturing site selection as long as compliance and delivery standards are met. The solicitation is accessible through the DIBBS platform, and while no set-aside provisions or point of contact information is provided, bidders are expected to demonstrate proven capability in producing pharmaceutical-grade chemical solutions with validated quality systems and documented adherence to medical manufacturing regulations.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 18 hours ago

DEADLINE

in 6 days
View Details

More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

Same awarding agency